Outlook Therapeutics OTLK
NASDAQ OTLK
$0.63 +0.00 (+0.74%)
At close: Sep 29, 2026 · 4:00 PM EDT

Outlook Therapeutics (OTLK) Notes Payables (2015 - 2025)

Updated

Outlook Therapeutics' Notes Payables was $29.95 million in fiscal Q4 2025 (quarter ended Sep 30, 2025).

Analysis

Outlook Therapeutics (OTLK) Notes Payables (2015 - 2025) Analysis & Trends

From fiscal Q4 2015 onward, Outlook Therapeutics has reported Notes Payables for 21 quarters.

  • Notes Payables shows a five-year compound annual growth rate of 52.7% (FY2020 to FY2025).
  • The fiscal Q4 2025 figure marks the highest quarterly Notes Payables in data going back to fiscal Q4 2015.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Johnson & Johnson 655.56 Bn 574.09 Bn 17.26 Bn
2 AbbVie 470.94 Bn 444.10 Bn 12.70 Bn
3 Merck 367.14 Bn 321.57 Bn 12.21 Bn
4 Novartis Ag 280.33 Bn 236.20 Bn 11.24 Bn
5 Astrazeneca 257.78 Bn 231.34 Bn 12.86 Bn
6 Amgen 226.04 Bn 181.44 Bn 7.24 Bn
7 Gilead Sciences 188.89 Bn 163.01 Bn 6.22 Bn
8 Pfizer 163.75 Bn 110.70 Bn 10.94 Bn
9 Vertex Pharmaceuticals 133.68 Bn 105.69 Bn 2.84 Bn
10 Outlook Therapeutics 84.78 Mn 49.03 Mn -8,265.00
Historic Data

Historic Data

Download Data
DateValue
Sep 30, 2025 29.95 Mn
Sep 30, 2020 3.61 Mn
Jun 30, 2020 3.61 Mn
Mar 31, 2020 3.61 Mn
Dec 31, 2019 3.61 Mn
Sep 30, 2019 3.61 Mn
Jun 30, 2019 3.61 Mn
Mar 31, 2019 3.61 Mn
Dec 31, 2018 4.61 Mn
Sep 30, 2018 4.61 Mn
Jun 30, 2018 4.61 Mn
Mar 31, 2018 4.61 Mn
Dec 31, 2017 4.61 Mn
Sep 30, 2017 4.61 Mn
Jun 30, 2017 4.61 Mn
Mar 31, 2017 4.61 Mn
Dec 31, 2016 4.61 Mn
Sep 30, 2016 4.61 Mn
Jun 30, 2016 4.61 Mn
Mar 31, 2016 9.65 Mn
API Access

Outlook Therapeutics Notes Payables API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=notes-payables&ticker=OTLK&period=max&api_key=YOUR_API_KEY